Coherus Oncology, Inc. - 8-K Filing
Coherus Oncology reported Q1 2026 net revenue of $12.3 million, with LOQTORZI® contributing $11.8 million (down 5% from Q4 but up 61% YoY). The company ended the quarter with $167.0 million in cash and announced a public equity offering that raised $53.6 million net proceeds. It also provided updates on clinical trials for tagmokitug, including Phase 1b studies across multiple cancers, and completed enrollment in its Phase 2 trial of casdozokitug for hepatocellular carcinoma. (Items: 2.02 Results of Operations and Financial Conditions, 9.01 Financial Statements and Exhibits)
Tickers: $CHRS